Temporal arteritis may be due to shingles virus

January 25, 2016

Headache is usually the main presenting symptom of temporal arteritis (also known as giant cell arteritis, or GCA), which is caused by inflammation of blood vessels. This condition happens almost exclusively in the elderly. It presents with a severe headache, which is often one-sided. Some, but not all patients have swelling and tenderness of their temporal artery at the temple. This is a serious condition because it damages blood vessels and can cause strokes, loss of vision, and other complications. The diagnosis is made by blood tests (C-reactive protein, or CRP and erythrocyte sedimentation rate, or ESR) and temporal artery biopsy. However, even the biopsy sometimes does not show the inflammation. The treatment consists of steroid medications, such as prednisone. Prednisone is usually very effective. Unfortunately, prednisone needs to be taken for years if not for the rest of the person’s life and when it is used for long periods, it has many potentially dangerous side effects.

A recent study published in JAMA Neurology showed that many patients with biopsy-proven giant cell arteritis have an infection with varicella-zoster virus. This virus is also responsible for shingles and chickenpox

The researchers reviewed samples of temporal arteries for the presence of varicella-zoster virus. It was found in 68 of 93 (73%) of temporal arteries of patients with the disease, compared with 11 of 49 (22%) normals.

The authors concluded that in patients with clinically suspected GCA, prevalence of the virus in their temporal arteries is similar independent of whether biopsy results are negative or positive. They also felt that “Antiviral treatment may confer additional benefit to patients with biopsy-negative GCA treated with corticosteroids, although the optimal antiviral regimen remains to be determined”, and that “Considering that antiviral medications such as Acyclovir are very safe, it is reasonable to give them to all patients with temporal arteritis.”

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe